IL2 and renal cell carcinoma: However, in a single centre experience, Motzer et al. have reported a significant rise in 2-year-survival rate from 3% (without therapy) to 20% (after interleukin-2, interferon alpha or both) in 670 patients with metastatic RCC.9 Selective multi target receptor tyrosine-kinase inhibitors (TKIs), like sunitinib and sorafenib, have been recently approved as novel therapeutic antiangiogenetic agents for treatment of advanced RCC, with reported satisfactory results on progression-free survival and quality of life.10–13